Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 73362 | 4.2702 |
09:34 ET | 10922 | 4.25 |
09:36 ET | 14645 | 4.27 |
09:38 ET | 18712 | 4.27 |
09:39 ET | 18100 | 4.28 |
09:41 ET | 76648 | 4.3 |
09:43 ET | 102059 | 4.31 |
09:45 ET | 31817 | 4.3028 |
09:48 ET | 1267 | 4.305 |
09:50 ET | 4246 | 4.295 |
09:52 ET | 19335 | 4.275 |
09:54 ET | 2533 | 4.25 |
09:56 ET | 20182 | 4.265 |
09:57 ET | 7434 | 4.28 |
09:59 ET | 33098 | 4.26 |
10:01 ET | 38459 | 4.295 |
10:03 ET | 78805 | 4.31 |
10:06 ET | 63742 | 4.305 |
10:08 ET | 18659 | 4.32 |
10:10 ET | 171751 | 4.3085 |
10:12 ET | 33002 | 4.32 |
10:14 ET | 16724 | 4.315 |
10:15 ET | 7605 | 4.315 |
10:17 ET | 50511 | 4.36 |
10:19 ET | 24087 | 4.375 |
10:21 ET | 17192 | 4.375 |
10:24 ET | 44704 | 4.4 |
10:26 ET | 19825 | 4.405 |
10:28 ET | 22788 | 4.41 |
10:30 ET | 42441 | 4.3992 |
10:32 ET | 23385 | 4.395 |
10:33 ET | 427 | 4.395 |
10:35 ET | 41580 | 4.405 |
10:37 ET | 5905 | 4.4 |
10:39 ET | 14571 | 4.385 |
10:42 ET | 29674 | 4.37 |
10:44 ET | 1524 | 4.37 |
10:46 ET | 38976 | 4.365 |
10:48 ET | 16807 | 4.365 |
10:50 ET | 69061 | 4.35 |
10:51 ET | 16543 | 4.3639 |
10:53 ET | 12680 | 4.35 |
10:55 ET | 22232 | 4.345 |
10:57 ET | 44348 | 4.3401 |
11:00 ET | 8626 | 4.34 |
11:02 ET | 59081 | 4.345 |
11:04 ET | 7229 | 4.335 |
11:06 ET | 40202 | 4.335 |
11:08 ET | 9387 | 4.32 |
11:09 ET | 21313 | 4.325 |
11:11 ET | 18053 | 4.315 |
11:13 ET | 81774 | 4.32 |
11:15 ET | 19020 | 4.32 |
11:18 ET | 2378 | 4.32 |
11:20 ET | 2151 | 4.32 |
11:22 ET | 5506 | 4.325 |
11:24 ET | 8608 | 4.325 |
11:26 ET | 5659 | 4.325 |
11:27 ET | 16254 | 4.315 |
11:29 ET | 15556 | 4.315 |
11:31 ET | 13297 | 4.305 |
11:33 ET | 1625 | 4.305 |
11:36 ET | 28465 | 4.305 |
11:38 ET | 34653 | 4.315 |
11:40 ET | 62884 | 4.32 |
11:42 ET | 4162 | 4.325 |
11:44 ET | 7207 | 4.325 |
11:45 ET | 33975 | 4.32 |
11:47 ET | 19232 | 4.325 |
11:49 ET | 16003 | 4.315 |
11:51 ET | 1690 | 4.3192 |
11:54 ET | 300 | 4.32 |
11:56 ET | 4094 | 4.3196 |
11:58 ET | 13711 | 4.325 |
12:00 ET | 3410 | 4.325 |
12:02 ET | 2741 | 4.32 |
12:03 ET | 35770 | 4.32 |
12:05 ET | 8446 | 4.325 |
12:07 ET | 1109 | 4.33 |
12:09 ET | 2851 | 4.33 |
12:12 ET | 15740 | 4.335 |
12:14 ET | 3816 | 4.335 |
12:16 ET | 1000 | 4.33 |
12:18 ET | 14201 | 4.325 |
12:20 ET | 1500 | 4.325 |
12:21 ET | 11412 | 4.32 |
12:23 ET | 7885 | 4.325 |
12:25 ET | 15887 | 4.33 |
12:27 ET | 14664 | 4.325 |
12:30 ET | 2668 | 4.325 |
12:32 ET | 5573 | 4.325 |
12:34 ET | 3185 | 4.325 |
12:36 ET | 4085 | 4.325 |
12:38 ET | 6673 | 4.32 |
12:39 ET | 7025 | 4.325 |
12:41 ET | 7568 | 4.325 |
12:43 ET | 8887 | 4.32 |
12:45 ET | 46904 | 4.325 |
12:48 ET | 27559 | 4.335 |
12:50 ET | 52111 | 4.34 |
12:52 ET | 85240 | 4.34 |
12:54 ET | 34031 | 4.3483 |
12:56 ET | 20478 | 4.345 |
12:57 ET | 80096 | 4.345 |
12:59 ET | 166330 | 4.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.6B | -12.6x | --- |
MoonLake Immunotherapeutics | 2.7B | -56.3x | --- |
Xenon Pharmaceuticals Inc | 2.7B | -13.3x | --- |
SpringWorks Therapeutics Inc | 2.8B | -7.2x | --- |
IDEAYA Biosciences Inc | 2.5B | -16.6x | --- |
Celldex Therapeutics Inc | 2.4B | -12.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.6x |
Price/Sales (TTM) | 4,973.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.